IFIH1 and dermatomyositis: The anti-MDA5 antibody is frequently detected among DM patients in Asia (36.6% (53/145 cases) in China, and 15.8% (26/165 cases) in Japan) [16] and at a low frequency (2.8% (21/748 cases)) in a cohort of DM patients in a combined European cohort in which 87.4% of enrolled patients were Caucasian [17].